[{"NetIncomeLoss_1_Q3_USD":-20952000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q3_USD":30403000.0,"OperatingLeaseLiabilityNoncurrent_0_Q3_USD":3314000.0,"AdditionalPaidInCapitalCommonStock_0_Q3_USD":1350736000.0,"ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_3_Q3_USD":3690000.0,"IncreaseDecreaseInOtherAccruedLiabilities_3_Q3_USD":2563000.0,"OperatingLeaseLiability_0_Q3_USD":12900000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3_Q3_shares":170297000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q3_shares":170886000.0,"DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_0_Q3_USD":38488000.0,"CommitmentsAndContingencies_0_Q3_USD":null,"ValuationAllowancesAndReservesChargedToCostAndExpense_3_Q3_USD":12060000.0,"InterestPaidNet_3_Q3_USD":1094000.0,"PaymentsToAcquireShortTermInvestments_3_Q3_USD":117076000.0,"OtherAssetsNoncurrent_0_Q3_USD":935000.0,"InventoryFinishedGoods_0_Q3_USD":1410000.0,"NetCashProvidedByUsedInInvestingActivities_3_Q3_USD":-86524000.0,"AssetsCurrent_0_Q3_USD":171104000.0,"LongTermDebt_0_Q3_USD":20000000.0,"SellingGeneralAndAdministrativeExpense_3_Q3_USD":67376000.0,"SellingGeneralAndAdministrativeExpense_1_Q3_USD":22877000.0,"CostOfGoodsAndServicesSold_3_Q3_USD":596000.0,"CostOfGoodsAndServicesSold_1_Q3_USD":151000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3_Q3_shares":9454000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q3_shares":31037000.0,"StockIssuedDuringPeriodValueShareBasedCompensation_1_Q3_USD":274000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0_Q3_USD":877000.0,"DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_0_Q3_security":19.0,"Assets_0_Q3_USD":186518000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q3_USD":8000.0,"IncreaseDecreaseInAccountsPayable_3_Q3_USD":-656000.0,"ComprehensiveIncomeNetOfTax_1_Q3_USD":-20951000.0,"ComprehensiveIncomeNetOfTax_3_Q3_USD":4739000.0,"ShortTermInvestments_0_Q3_USD":112743000.0,"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q3_USD":2529000.0,"IncreaseDecreaseInOtherNoncurrentAssets_3_Q3_USD":111000.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q3_USD":13891000.0,"InventoryRawMaterials_0_Q3_USD":5142000.0,"ValuationAllowancesAndReservesDeductions_3_Q3_USD":10827000.0,"EarningsPerShareBasic_1_Q3_USD":-0.12,"EarningsPerShareBasic_3_Q3_USD":0.03,"OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_1_Q3_USD":1000.0,"OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_3_Q3_USD":12000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_3_Q3_shares":176452000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q3_shares":170886000.0,"AccountsReceivableNetCurrent_0_Q3_USD":14991000.0,"IncomeTaxExpenseBenefit_3_Q3_USD":665000.0,"IncomeTaxExpenseBenefit_1_Q3_USD":-136000.0,"InvestmentIncomeNetAmortizationOfDiscountAndPremium_3_Q3_USD":-171000.0,"CommonStockValue_0_Q3_USD":171000.0,"DepreciationDepletionAndAmortization_3_Q3_USD":758000.0,"IncreaseDecreaseInEmployeeRelatedLiabilities_3_Q3_USD":-131000.0,"ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_3_Q3_USD":51933000.0,"ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1_Q3_USD":18300000.0,"NetCashProvidedByUsedInFinancingActivities_3_Q3_USD":61590000.0,"DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_0_Q3_USD":7000.0,"CostsAndExpenses_3_Q3_USD":119905000.0,"CostsAndExpenses_1_Q3_USD":41328000.0,"CashCashEquivalentsAndShortTermInvestments_0_Q3_USD":143146000.0,"IncreaseDecreaseInInventories_3_Q3_USD":5325000.0,"NetIncomeLossAvailableToCommonStockholdersBasic_1_Q3_USD":-20952000.0,"NetIncomeLossAvailableToCommonStockholdersBasic_3_Q3_USD":4727000.0,"ShareBasedCompensation_3_Q3_USD":7147000.0,"OperatingLeaseRightOfUseAsset_0_Q3_USD":11824000.0,"LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_0_Q3_USD":2500000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3_Q3_USD":-8113000.0,"EarningsPerShareDiluted_3_Q3_USD":0.03,"EarningsPerShareDiluted_1_Q3_USD":-0.12,"InvestmentsFairValueDisclosure_0_Q3_USD":114742000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3_Q3_USD":5392000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q3_USD":-21088000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q3_USD":2237000.0,"ValuationAllowancesAndReservesBalance_0_Q3_USD":7298000.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":24964000.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":170297000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":170886000.0,"InventoryWorkInProcess_0_Q3_USD":483000.0,"LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0_Q3_USD":10485000.0,"LiabilitiesCurrent_0_Q3_USD":59282000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_3_Q3_USD":30000.0,"AccountsPayableCurrent_0_Q3_USD":3144000.0,"InterestExpense_3_Q3_USD":3561000.0,"InterestExpense_1_Q3_USD":1317000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q3_USD":5932000.0,"OtherAccruedLiabilitiesCurrent_0_Q3_USD":13486000.0,"SubleaseIncome_3_Q3_USD":3965000.0,"SubleaseIncome_1_Q3_USD":1331000.0,"DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_0_Q3_position":0.0,"WeightedAverageNumberDilutedSharesOutstandingAdjustment_3_Q3_shares":6155000.0,"OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_3_Q3_USD":0.0,"OperatingLeasePayments_3_Q3_USD":7554000.0,"OperatingLeasePayments_1_Q3_USD":2529000.0,"LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_0_Q3_USD":10000000.0,"PropertyPlantAndEquipmentNet_0_Q3_USD":2655000.0,"NetIncomeLoss_3_Q3_USD":4727000.0,"IncreaseDecreaseInAccountsReceivable_3_Q3_USD":-982000.0,"LongTermLoansPayable_0_Q3_USD":19887000.0,"LeaseCost_1_Q3_USD":1599000.0,"RetainedEarningsAccumulatedDeficit_0_Q3_USD":-1301245000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_3_Q3_USD":128827000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q3_USD":21543000.0,"OperatingIncomeLoss_3_Q3_USD":8922000.0,"OperatingIncomeLoss_1_Q3_USD":-19785000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0_Q3_shares":10403690.0,"InventoryNet_0_Q3_USD":7035000.0,"InvestmentIncomeInterest_3_Q3_USD":31000.0,"InvestmentIncomeInterest_1_Q3_USD":14000.0,"ContractWithCustomerLiabilityCurrent_0_Q3_USD":3157000.0,"PreferredStockValue_0_Q3_USD":null,"OperatingLeaseCost_3_Q3_USD":4020000.0,"OperatingLeaseCost_1_Q3_USD":1340000.0,"LiabilitiesAndStockholdersEquity_0_Q3_USD":186518000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q3_USD":9461000.0,"LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_0_Q3_USD":7500000.0,"AllocatedShareBasedCompensationExpense_3_Q3_USD":7147000.0,"AllocatedShareBasedCompensationExpense_1_Q3_USD":2202000.0,"OperatingLeaseLiabilityCurrent_0_Q3_USD":9574000.0,"ProfitLoss_3_Q3_USD":4727000.0,"OtherLiabilitiesNoncurrent_0_Q3_USD":54365000.0,"OtherLiabilitiesCurrent_0_Q3_USD":10985000.0,"StockholdersEquity_0_Q3_USD":49670000.0,"PaymentsToAcquirePropertyPlantAndEquipment_3_Q3_USD":648000.0,"AccretionExpense_3_Q3_USD":1900000.0,"AccretionExpense_1_Q3_USD":836000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q3_USD":114734000.0,"ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_3_Q3_USD":31200000.0,"VariableLeaseCost_3_Q3_USD":651000.0,"VariableLeaseCost_1_Q3_USD":259000.0,"LeaseCost_3_Q3_USD":4671000.0,"IncreaseDecreaseInContractWithCustomerLiability_3_Q3_USD":139000.0,"Ticker":"RIGL","CIK":"1034842","name":"RIGEL PHARMACEUTICALS INC","OfficialName":"Rigel Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20210930","fy":"2021.0","fp":"Q3","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"488447519.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20211102"}]